Cohance Lifesciences to hold board meeting for financial results

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced that its board of directors will convene a meeting on Wednesday, November 12, 2025. The primary agenda for this meeting is to consider and approve the unaudited financial results, both standalone and consolidated, for the quarter and half year ending September 30, 2025.

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's securities will be closed from October 1, 2025, to November 14, 2025, inclusive of both days. This closure is standard practice ahead of significant financial disclosures.

The announcement was made by Kundan Kumar Jha, company secretary, compliance officer, and head-legal for Cohance Lifesciences Limited, and was communicated to both BSE Limited and the National Stock Exchange of India Limited on September 27, 2025.